Modeling immune responses to autologous and allogeneic human stem cell–derived islet grafts in vivo
JCI Insight · 2026
DOI: 10.1172/jci.insight.200738 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2026. Verfasst von Camillo Bechi Genzano und 18 weiteren Autor:innen. Beteiligte Einrichtung: Columbia Center for Translational Immunology and Department of Medicine. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1, Islets of Langerhans. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Breakthrough T1D, NIAID.
Abstract (Originalsprache)
Stem cell–derived β cells offer a promising approach for type 1 diabetes (T1D) treatment. However, the processes of graft infiltration and rejection by immune cells remain poorly understood in humans. In this study, autologous or allogeneic stem cell–derived islets (SC-islets) were transplanted in human immune system mice and analyzed 14 to 18 weeks later. Imaging mass cytometry revealed unique characteristics of SC-islet grafts, including a high percentage of glucagon + cells and the presence of cysts and CD57 + enterochromaffin cells, features not typically observed in endogenous or transplanted allogeneic primary pancreatic islets. Allogeneic SC-islet grafts exhibited heavy immune infiltration, cell proliferation, and pro-fibrotic processes, whereas autologous grafts showed minimal infiltration and little fibrosis. In some mice, autologous T cells expressing islet antigen-reactive (IAR) T cell receptors (TCRs) were adoptively transferred. Three weeks after transfer, autologous grafts injected with IAR-TCR + T cells showed negligible immune infiltration, even though IAR-TCR + T cells were detected in the spleen. Under the conditions tested, human SC-islet grafts were not rejected by an autologous immune system, even in the presence of autoreactive T cells, pointing to several limitations that remain to be addressed for a model of spontaneous autologous SC-islet infiltration and destruction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Columbia Center for Translational Immunology and Department of Medicine.
- Naomi Berrie Diabetes Center, and.
- Department of Pediatrics and Columbia Stem Cell Initiative, Columbia University Medical Center, New York, New York, USA.
- Department of Genetics and Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Bioengineering Graduate Program, University of Kansas, Lawrence, Kansas, USA.
- Department of Biomedical Engineering and.
Förderung
- NIDDK NIH HHS
- Breakthrough T1D
- NIAID
- American Diabetes Association
- NIDDK
- National Cancer Institute
Zitieren
APA
Bechi Genzano, C., Zanetti, G., Du, Q., Traum, D., Lahori, D., Downes, G. M., Bhatele, S. A., Ding, X., Apley, K. D., Firdessa Fite, R., Ishahak, M., Sanchez-Castro, E. E., Millman, J. R., Luo, Y., Kaestner, K. H., Berkland, C., Egli, D., Sykes, M., & Creusot, R. J. (2026). Modeling immune responses to autologous and allogeneic human stem cell–derived islet grafts in vivo. JCI Insight. https://doi.org/10.1172/jci.insight.200738
Vancouver
Bechi Genzano C, Zanetti G, Du Q, Traum D, Lahori D, Downes GM, et al. Modeling immune responses to autologous and allogeneic human stem cell–derived islet grafts in vivo. JCI Insight. 2026. doi:10.1172/jci.insight.200738
BibTeX
@article{BechiGenzano2026,
author = {Bechi Genzano, Camillo and Zanetti, Giorgia and Du, Qian and Traum, Daniel and Lahori, Deeksha and Downes, Grant M and Bhatele, Sakshi A and Ding, Xiaolan and Apley, Kyle D and Firdessa Fite, Rebuma and Ishahak, Matthew and Sanchez-Castro, Enrique Eduardo and Millman, Jeffrey R and Luo, Yiming and Kaestner, Klaus H and Berkland, Cory and Egli, Dieter and Sykes, Megan and Creusot, Remi J},
title = {Modeling immune responses to autologous and allogeneic human stem cell–derived islet grafts in vivo},
journal = {JCI Insight},
year = {2026},
doi = {10.1172/jci.insight.200738}
}
EUVIMED